Get the latest market trends in your inbox

Stay on top of the latest market trends and economic insights with the Axios Markets newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa-St. Petersburg news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Sarah Grillo/Axios

President Trump's upcoming speech on drug prices will probably stick to small-ball ideas. But small-ball doesn't necessarily mean no impact.

Reality check: There are a lot of legitimate ways to bring down drug costs; there are also a lot of empty gestures masquerading as real change. Here's a guide to the kinds of ideas and the odds that they'll actually happen.

Bucket 1: Move the costs around

The big picture: These proposals could reduce what patients pay for drugs, but not necessarily what the health care system as a whole pays.

How it works: The gist here is to rearrange existing discounts within the drug supply chain, usually by targeting the various middlemen between drug companies and patients.

  • One idea is to make pharmacy benefit managers, who negotiate big discounts on behalf of insurers and employers, pass more of those savings on to patients at the pharmacy counter.
  • The administration has already announced changes to a program that provides discounted drugs to hospitals, and Congress may go even further.

Threat level: This is where the administration has been most active so far, and politically, there’s a lot of low-hanging fruit in this set of policies.

What they’re saying: All of this fits with the industry’s larger worldview, which is that new drugs are worth the money, but patients should have to foot less of the bill on their own. Consumer advocates don’t oppose these policies, but they say this bucket doesn’t get at the heart of the problem.

Bucket 2: Increase competition

The big picture: Some conservatives want to tackle the underlying price of drugs, but they want to do it by fostering a more competitive market, rather than through price controls.

How it works: New drugs are entitled to five to 12 years of sales, depending on the type of drug, before a generic version can come to market. That window usually ends up being longer, though, because of drugs’ patent protections.

  • The FDA has largely cleared out its backlog of generic drugs waiting for approval, and commissioner Scott Gottlieb hopes to jump-start the lagging market for generic versions of especially complex drugs.
  • No one formally opposes more generics, but brand-name drug makers have been accused of unfairly denying generics the samples they need to develop their products. There’s a bill in Congress to address that; industry opposes it.
  • Critics also say drug companies are abusing the patent system by taking out patents on even the most minor component of a drug, then reformulating those components and taking out a whole new “thicket” of patents — keeping generics at bay even longer.

Threat level: Health and Human Services secretary Alex Azar — himself a former pharmaceutical executive — said in his confirmation hearing that he would be willing to look at patent “gaming.”

What they’re saying: The advocacy group Patients for Affordable Drugs says some of these ideas, including the bill on product samples, would make a real difference. Industry, meanwhile, will probably have to concede that some “gaming” does occur, but acceding to the most aggressive regulatory changes would cost drug makers billions.

Bucket 3: Reduce the prices

The big picture: Bucket 1 addresses who pays, but not the underlying prices of drugs. Bucket 2 tries to get the market to deliver lower prices. Bucket 3 demands them.

How it works: The marquee policy here is for Medicare to negotiate — or simply to dictate — what it will pay for drugs.

  • Democrats say that would not only lower costs for seniors and Medicare, but for everyone, because private insurance wouldn’t pay much more than Medicare does. Drug companies say it would dry up innovation and research.

Threat level: Trump has endorsed price negotiations in the past, which makes industry nervous, but the policy remain very much a long shot.

What they’re saying: Traditional conservatives — like Azar, Gottlieb, Vice President Mike Pence, and congressional GOP leaders — have long hated this idea. And as much as it’s still a holy grail on the left, the advocacy groups most active on this issue are also focusing on more achievable goals.

Go deeper

Broncos and 49ers the latest NFL teams impacted by coronavirus crisis

From left, Denver Broncos quarterbacks Drew Lock, Brett Rypien and Jeff Driskel during an August training session at UCHealth Training Center in Englewood, Colorado. Photo: Justin Edmonds/Getty Images

The COVID-19 pandemic has thrown the NFL season into chaos, with all Denver Broncos quarterbacks sidelined, the San Francisco 49ers left without a home or practice ground and much of the Baltimore Ravens team unavailable, per AP.

Driving the news: The Broncos confirmed in a statement Saturday night that quarterbacks Drew Lock, Brett Rypien and Blake Bortles were identified as "high-risk COVID-19 close contacts" and will follow the NFL's mandatory five-day quarantine, making them ineligible for Sunday's game against New Orleans.

Updated 11 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Health: WHO: AstraZeneca vaccine must be evaluated on "more than a press release."
  2. Politics: McConnell temporarily halts in-person lunches for GOP caucus.
  3. Economy: Safety nets to disappear in DecemberAmazon hires 1,400 workers a day throughout pandemic.
  4. Education: U.S. public school enrollment drops as pandemic persists.
  5. Cities: Surge in cases forces San Francisco to impose curfew — Los Angeles County issues stay-at-home order, limits gatherings.
  6. Sports: NFL bans in-person team activities Monday, Tuesday due to COVID-19 surge — NBA announces new coronavirus protocols.
  7. World: London police arrest more than 150 during anti-lockdown protests — Thailand, Philippines sign deal with AstraZeneca for vaccine.

Tony Hsieh, longtime Zappos CEO, dies at 46

Tony Hsieh. Photo: FilmMagic/FilmMagic

Tony Hsieh, the longtime ex-chief executive of Zappos, died on Friday after being injured in a house fire, his lawyer told the Las Vegas Review-Journal. He was 46.

The big picture: Hsieh was known for his unique approach to management, and following the 2008 recession his ongoing investment and efforts to revitalize the downtown Las Vegas area.